Scancell is a clinical-stage immuno-oncology specialist. The key value drivers are iSCIB1+, the lead ImmunoBody programme, and Modi-1, the lead Moditope programme. The novel GlyMab glycan antibodies are earlier in development.
Scancell is a clinical-stage oncology specialist developing immunotherapies. Its differentiated portfolio is anchored around two novel ‘off-the-shelf’ platforms, ImmunoBody and Moditope, complemented by the GlyMab antibody platform that targets tumour-associated glycans. Collectively, these three platforms offer broad potential across a range of solid tumours. Following FDA sign off on the proposed study design, lead ImmunoBody asset iSCIB1+ is poised to enter a registrational study during 2026, with funding secured through the proposed UK placing, Neuphoria reverse merger and US PIPE transactions. SCOPE Phase II data continues to mature, with further updates expected in H1 calendar 2027. For Moditope, interim data from the renal cell carcinoma (RCC) cohort of the ModiFY study will provide important insights into the potential synergy of lead asset Modi-1 when combined with checkpoint inhibitor therapy. Alongside, the GlyMab portfolio continues to produce compelling preclinical results, with the Genmab partnered assets expected to trigger a near-term development milestone on clinical entry.
| Symbol | Primary exchanges |
| SCLP | AIM London |